Related Experiment Videos
Glucose insulin potassium infusion improves systolic function in patients with chronic ischemic cardiomyopathy
Yves Cottin1, Isabelle Lhuillier, Laurent Gilson
1Cardiology Department, University Hospital, Dijon, France. yves.cottin@chu-dijon.fr
Insights
Glucose-insulin-potassium (GIK) infusion improved systolic function in patients with stable coronary disease and low ejection fraction. Echocardiography showed enhanced wall motion and ejection fraction after GIK treatment.
Area of Science:
- Cardiology
- Cardiovascular Physiology
Background:
- Stable coronary disease (SCD) with reduced ejection fraction (EF) presents a significant clinical challenge.
- Assessing interventions to improve systolic function in these patients is crucial.
Purpose of the Study:
- To evaluate the effects of glucose-insulin-potassium (GIK) infusion on systolic function in patients with SCD and EF <45%.
Main Methods:
- Twelve male patients with SCD and EF <45% underwent echocardiography.
- GIK was infused over 20 minutes, with hemodynamic and echocardiographic measurements taken at baseline, during, and post-infusion.
Main Results:
- A significant decrease in wall motion score index (WMSI) was observed at 20 minutes post-infusion (P<0.05).
- Ejection fraction (EF) significantly increased at 40 and 60 minutes post-infusion compared to baseline (P<0.01).
- WMSI also decreased at 40 and 60 minutes post-infusion (P<0.01).
Conclusions:
- GIK infusion demonstrates a positive impact on systolic function in patients with SCD and reduced EF.
- Further research is warranted to explore the therapeutic and diagnostic potential of short-term GIK infusion in this patient population.
Objective:
We assessed the effects of glucose-insulin-potassium (GIK) by echocardiography in stable patients with ischemic dysfunction.
Methods:
Twelve male patients with stable coronary disease (SCD) and ejection fraction (EF) <45% were studied for systolic function. GIK (glucose 30%, 300 insulin units and KCl 6 g/l) was infused at 1 ml/kg per h over 20 min. Hemodynamic and echocardiographic measurements were recorded at rest (T(0)), at the end (20 min) of GIK infusion (T+20), 20 and 40 min after the end of the infusion (T+40 and T+60).
Results:
At T+20, a significant decrease in WMSI (wall motion score index) was observed compared with T(0) (2.16+/-0.14 vs. 2.30+/-0.16: P<0.05). An increase in EF was reported at T+40 and T+60 compared with T(0) (44.1+/-7.8% and 53.3+/-11.6% vs. 35.6+/-4.5%, respectively: P<0.01). A decrease in WMSI was observed at T+40 and T+60 compared with rest (2.02+/-0.17 and 1.93+/-0.11 vs. 2.30+/-0.16, respectively: P<0.01).
Conclusion:
Our present work suggests that GIK infusion improves systolic function in patients with SCD and ejection fraction <45%. Further studies are needed to determine if short-term GIK infusion could be useful for therapeutic or diagnostic strategies in these patients.